No connection

Search Results

EBS vs UNH

EBS
Emergent BioSolutions Inc.
BEARISH
Price
$8.03
Market Cap
$414.7M
Sector
Healthcare
AI Confidence
85%
UNH
UnitedHealth Group Incorporated
NEUTRAL
Price
$323.48
Market Cap
$293.61B
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
EBS
8.63
UNH
24.43
Forward P/E
EBS
2.69
UNH
16.08
P/B Ratio
EBS
0.8
UNH
3.11
P/S Ratio
EBS
0.56
UNH
0.66
EV/EBITDA
EBS
3.8
UNH
16.47

Profitability

Gross Margin
EBS
49.44%
UNH
18.53%
Operating Margin
EBS
-15.2%
UNH
0.34%
Profit Margin
EBS
7.08%
UNH
2.69%
ROE
EBS
10.46%
UNH
12.54%
ROA
EBS
5.33%
UNH
3.9%

Growth

Revenue Growth
EBS
-23.6%
UNH
12.3%
Earnings Growth
EBS
--
UNH
-99.9%

Financial Health

Debt/Equity
EBS
1.12
UNH
0.82
Current Ratio
EBS
5.01
UNH
0.79
Quick Ratio
EBS
2.19
UNH
0.7

Dividends

Dividend Yield
EBS
--
UNH
2.73%
Payout Ratio
EBS
0.0%
UNH
65.99%

AI Verdict

EBS BEARISH

EBS presents as a classic value trap, characterized by a stable but mediocre Piotroski F-Score of 4/9 and a significant disconnect between its Graham Number ($14.48) and Intrinsic Value ($6.51). While the stock appears cheap on a P/E and P/S basis, this is offset by a severe revenue contraction of -23.6% YoY and negative operating margins (-15.20%). The combination of bearish insider sentiment, a 0/100 technical trend, and extreme earnings volatility suggests that the current price is not yet reflecting the full extent of the fundamental decay.

Strengths
Strong short-term liquidity with a Current Ratio of 5.01
Low valuation multiples (P/E 8.63, P/S 0.56)
Healthy Gross Margin of 49.44%
Risks
Significant revenue decline (-23.6% YoY and -24.04% Q/Q)
Negative operating margins indicating an unsustainable core business model
Bearish insider activity with consistent selling and zero buying
UNH NEUTRAL

UnitedHealth Group presents a conflicted profile with a stable but mediocre Piotroski F-Score of 4/9 and a significant disconnect between current price ($323.48) and defensive fair value (Graham Number: $175.91). While revenue growth remains robust at 12.3%, the company has suffered a catastrophic collapse in YoY earnings growth (-99.9%), suggesting severe short-term headwinds or one-time accounting shocks. Technical trends are currently bearish (0/100), though a recent one-month bounce and a favorable Forward P/E of 16.08 indicate analyst expectations of a recovery. The stock is currently trading at a significant premium to its intrinsic value, relying heavily on its market dominance and future earnings normalization.

Strengths
Strong consistent revenue growth (12.3% YoY)
Manageable Debt/Equity ratio of 0.82
Attractive Forward P/E (16.08) compared to current P/E (24.43)
Risks
Extreme earnings volatility (YoY Earnings Growth -99.9%)
Poor liquidity indicated by a Current Ratio of 0.79
Extremely thin operating margins (0.34%)

Compare Another Pair

EBS vs UNH: Head-to-Head Comparison

This page compares Emergent BioSolutions Inc. (EBS) and UnitedHealth Group Incorporated (UNH) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI Chat
Markets
Profile